Sanofi (SNY)
| Market Cap | 131.54B |
| Revenue (ttm) | 50.96B |
| Net Income (ttm) | 4.53B |
| Shares Out | 2.51B |
| EPS (ttm) | 1.83 |
| PE Ratio | 28.79 |
| Forward PE | 11.14 |
| Dividend | $2.04 (3.89%) |
| Ex-Dividend Date | May 9, 2024 |
| Volume | 1,973,778 |
| Open | 52.67 |
| Previous Close | 53.10 |
| Day's Range | 52.37 - 52.85 |
| 52-Week Range | 42.63 - 55.72 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 57.50 (+9.73%) |
| Earnings Date | Jul 25, 2024 |
About SNY
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric ... [Read more]
Financial Performance
In 2023, Sanofi's revenue was 46.03 billion, an increase of 1.42% compared to the previous year's 45.39 billion. Earnings were 5.40 billion, a decrease of -35.49%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SNY stock is "Buy." The 12-month stock price forecast is $57.5, which is an increase of 9.73% from the latest price.
News
Press Release: Online availability of Sanofi's half-year financial report for 2024
Online availability of Sanofi's half-year financial report for 2024 Paris, July 25, 2024. Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available and ...
Sanofi bumps up full-year forecast after strong Q2 profit
Sanofi's second-quarter profit rose 3.2% on strong demand for its blockbuster asthma drug Dupixent and better-than-expected sales of new launches, with the company now expecting a stable full-year pro...
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
PARSIPPANY, N.J. & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Sanofi today announced an update to the timing for th...
Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A ALTUVIIIO provides high-sustained factor levels wit...
Sanofi to invest $437 mln in India global centre, double its workforce
French drugmaker Sanofi plans to invest 400 million euros ($437.24 million) in its global capacity centre (GCC) in India by the end of the decade, as it aims to expand and more than double its workfor...
Sanofi ships U.S. influenza vaccines for the 2024/25 season
Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. ...
Cosette Pharmaceuticals Acquires Ambien® and Ambien CR® (Zolpidem Tartrate) Tabs from Sanofi US in the US Market
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #ambien--Cosette Pharmaceuticals, Inc. (“Cosette”), a US-based specialty pharmaceutical company, has completed the acquisition of Ambien® and Ambien CR® in the Uni...
Bpifrance eyes investment in Sanofi's consumer health business
Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi's consumer health unit, Bloomberg News reported on Thursday.
Sanofi CEO on AI's Impact, Lung Disease Drug Clearance
Sanofi CEO Paul Hudson joins Caroline Hyde to discuss the company's integration of AI tools in everyday operations, the impact of AI on the biopharma sector, and the company's Dupixent drug getting cl...
EU approves Sanofi's Dupixent for 'smoker's lungs'
Sanofi and partner Regeneron on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a chronic lung disease, a rare case of the EU clearing a drug faster th...
Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two l...
Sanofi eyes German insulin investment of up to $1.6 bln, source says
French drugmaker Sanofi is nearing a decision to invest between 1.3 billion and 1.5 billion euros ($1.4-$1.6 billion) to upgrade its production of long-acting insulin shots in Germany, a person famili...
Sanofi eyes investment of up to $1.6 bln in Germany, Handelsblatt says
French drugmaker Sanofi is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major production site in Frankfurt, Germany, where it makes insulin bra...
German vaccine panel endorses Astra-Sanofi's RSV shot for infants
Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infecti...
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixen...
Sanofi-backed Formation Bio raises $372 million in late-stage funding round
AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi.
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Sanofi SA SNY is calling for initial bids for its $20 billion consumer health division.
Press Release: Availability of the Q2 2024 Aide-mémoire
Availability of the Q2 2024 Aide-mémoire Paris, France – June 25, 2024. Sanofi announced that its Q2 2024 Aide-mémoire is available on the "Investors" page of the company's website: https://www.sanofi...
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi's Executive Committee
Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi's Executive Committee Paris, June 21, 2024. Audrey Duval Derveloy, a seasoned healthcare industry leader and Sanofi F...
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the hemophilia portfolio reinforce Sanofi's commitment to bring potential first...
Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Small Molecule Therapeutics for Immunological Diseases
Belharra today announced a strategic collaboration with Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases.
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi's global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries.
FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung'
French drugmaker Sanofi and its partner Regeneron said on Friday the U.S. Food and Drug Administration (FDA) requested additional analyses on the efficacy of Dupixent as an add-on treatment in certain...
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 tria...